Suppr超能文献

[因有效的抗肿瘤治疗而停止对一名已确诊多发性骨髓瘤和肾衰竭患者的维持性透析]

[Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].

作者信息

Rosa Józef, Sydor Antoni, Jurczyszyn Artur, Zabawa-Hołyś Stanisława, Nowak Jacek, Czapkowicz-Gryszkiewicz Lilla, Sułowicz Władysław

机构信息

Oddział Chorób Wewnetrznych i Nefrologii, Szpitala Wojewódzkiego im. Sw. Łukasza w Tarnowie.

出版信息

Przegl Lek. 2010;67(7):547-50.

Abstract

Renal failure is a common complication in the course of multiple myeloma (MM). It is being observed in 20-40% of patients at the moment of disease diagnosis and in 10-36% of the cases dialysis treatment is required. Kidney damage is mainly caused by the toxic effect of monoclonal light chains, also known as Bence-Jones proteins produced by the pathological plasma cells. Light chains coaggregate with Tamm-Horsfall glycoprotein leading to casts formation in the distal nephron (cast nephropathy). Additional factors causing renal damage in MM may be dehydration, hypercalcemia, hyperuricemia as well as drug nephrotoxicity. We have described a 49 year-old woman diagnosed with IgA multiple myeloma at IIIB advance stage according to Durie and Salmona classification. The disease course was complicated by renal failure. Myeloma treatment (cyclophosphamide + talidomid + dexamethasone) was initiated simultaneously with hemodialysis therapy. Treatment with this was successful even though disease course was very severe and required longer-term hemodialysotherapy. Complete hematological remission was obtained and after 17 months of renal replacement therapy--hemodialysis treatment was ceased due to improvement of renal function. The presented case confirms the necessity of dialysis therapy initiation in every case of acute renal failure in the course of multiple myeloma--even when symptoms indicates an advanced stage of the disease. Initiation of dialysis therapy allows to initiate and continue the effective multiple myeloma treatment. This is the chance for recovery of renal function to such a level that dialysis treatment could be ceased, even after many months of dialysis therapy.

摘要

肾衰竭是多发性骨髓瘤(MM)病程中的常见并发症。在疾病诊断时,20%-40%的患者会出现肾衰竭,其中10%-36%的病例需要进行透析治疗。肾脏损伤主要由单克隆轻链的毒性作用引起,单克隆轻链也被称为病理性浆细胞产生的本-周蛋白。轻链与Tamm-Horsfall糖蛋白共同聚集,导致远端肾单位管型形成(管型肾病)。MM中导致肾损伤的其他因素可能包括脱水、高钙血症、高尿酸血症以及药物肾毒性。我们描述了一名49岁女性,根据Durie和Salmona分类,她被诊断为IIIB期进展期IgA多发性骨髓瘤。病程因肾衰竭而复杂化。在进行血液透析治疗的同时开始了骨髓瘤治疗(环磷酰胺+沙利度胺+地塞米松)。尽管病程非常严重且需要长期血液透析治疗,但这种治疗取得了成功。获得了完全血液学缓解,在进行17个月的肾脏替代治疗——血液透析治疗后,由于肾功能改善而停止了透析治疗。该病例证实了在多发性骨髓瘤病程中每例急性肾衰竭时都有必要开始透析治疗——即使症状表明疾病处于晚期。开始透析治疗能够启动并继续有效的多发性骨髓瘤治疗。这是使肾功能恢复到可以停止透析治疗的水平的机会,即使是在经过多个月的透析治疗之后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验